前列腺癌雄激素剥夺治疗男性骨健康与体成分不良反应的生活方式管理指南:更新
该综述评估了前列腺癌患者接受雄激素剥夺治疗(ADT)所致骨健康与体成分不良反应的现行临床指南,指出常规实践中患者仍存在中心性肥胖增加、骨丢失加速及血糖恶化,并提出基于运动与营养等生活方式干预证据的新建议。
要点
- 现行指南存在局限性,常规实践中ADT相关骨与代谢不良反应控制不佳。
- 新建议聚焦运动与营养等生活方式干预对骨健康和体成分的管理。
- 需关注中心性肥胖、骨丢失加速及血糖恶化等ADT相关不良反应。
核心结论
- 综述讨论现行指南的局限性,并提出基于运动与营养等生活方式干预证据的新建议以管理ADT相关骨健康与体成分不良反应。
研究设计与样本
- 综述评估了前列腺癌男性ADT所致骨健康与体成分不良反应管理的标准临床指南。
主要发现
- 评估指南在常规实践中的效果显示,患者仍持续出现中心性肥胖增加。
- 除非启动药物治疗,否则出现骨丢失加速和血糖恶化。
临床怎么用
- 作者提出基于新兴证据的新建议,尤其涉及运动与营养因素,以管理ADT相关骨健康与体成分不良反应。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Men treated with androgen deprivation therapy (ADT) for prostate cancer are prone to multiple treatment-induced adverse effects, particularly with regard to a deterioration in bone health and altered body composition including decreased lean tissue mass and increased fat mass. These alterations may partially explain the marked increased risk in osteoporosis, falls, fracture and cardiometabolic risk that has been observed in this population. METHODS: A review was conducted that assessed standard clinical guidelines for the management of ADT-induced adverse effects on bone health and body composition in men with prostate cancer. RESULTS: Currently, standard clinical guidelines exist for the management of various bone and metabolic ADT-induced adverse effects in men with prostate cancer. However, an evaluation of the effectiveness of these guidelines into routine practice revealed that men continued to experience increased central adiposity, and, unless pharmacotherapy was instituted, accelerated bone loss and worsening glycaemia occurred. CONCLUSIONS: This review discusses the current guidelines and some of the limitations, and proposes new recommendations based on emerging evidence regarding the efficacy of lifestyle interventions, particularly with regard to exercise and nutritional factors, to manage ADT-related adverse effects on bone health and body composition in men with prostate cancer.
引用
- Owen PJ, Daly RM, Livingston PM, et al. Lifestyle guidelines for managing adverse effects on bone health and body composition in men treated with androgen deprivation therapy for prostate cancer: an update. Prostate Cancer Prostatic Dis. 2017. PMID: 28117386. doi:10.1038/pcan.2016.69
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。